

**Freedom of Information Act 2000 – Request Reference FoI/23/552**  
**Cancer Treatment**

**Information Requested:**

- 1) Over the last 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:
  - A) Metastatic Melanoma
  - B) Adjuvant Melanoma
  - C) BRAF mutated Lung Cancer
  
- 2) Over the last 6 months, how many patients were treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases:
  - A) Metastatic Melanoma
  - B) Colorectal Cancer
  - C) Any other indications

**Response Details:**

Please find below the total figures of patients who were prescribed the combination of drugs listed, as requested, by Cardiff and Vale University Health Board (the UHB) Pharmacy.

Please note that the figures are representative of all departments, and all diseases and indications. The UHB is unable to confirm whether these figures relate specifically to cancer treatment.

- 1) After considering your request, the UHB believes that Section 40 of the Freedom of Information Act 2000 applies. Due to the low numbers of individuals involved, the UHB believes that, when considered with other information already available within the public domain, disclosure would result in the risk of individuals becoming identifiable. The data requested is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.
  
- 2) 0 patients.